One of the partially successful attempts is lomitapide, an inhibitor of both intestinal and hepatic MTTP, which impairs chylomicron and VLDL lipidation and is approved for the treatment of homozygous familial hypercholesterolemia, a rare disease caused by genetic mutations impairing lipid clearance from the blood by peripheral tissues (Perry, 2013). Here, MT-TP is linked to familial hypercholesterolemia.